• 약학회지
• /
• 제58권6호
• /
• pp.397-404
• /
• 2014

The Ministry of Health and Welfare proposed the "undergraduate program specializing in pharmaceutical industry" in 2013, as part of its roadmap to assist domestic pharmaceutical companies to become the top-tier pharma companies in near future and provide skilled personnel tailored for pharmaceutical industry. However, it is not clear whether this "undergraduate program" meets the needs of pharmaceutical industry, especially when the number of pharmacy students increased from 1,200 to 1,700 per year since 2009. The purpose of this paper is to identify which educational background is preferred by pharmaceutical companies, by surveying the CEOs of domestic pharmaceutical companies and referring to recruitment advertisements shown in medical newspapers, specified by the fields within the companies. Two independent reviewers referred to recruitment session in Yakup newspaper and Dailypharm from May 2012 until January 2014, focusing on recruitments from pharmaceutical companies targeting bachelors' degree holders with no prior experience. 749 recruitments were observed during the study period, more than 90% of which were provided by domestic pharmaceutical companies, and regardless of the companies being domestic or multinational, pharmaceutical companies' preference for pharmacists was remarkable (44.3% for domestic and 65.8% for multinational), and the preference was especially high in the fields such as Medical, R&D, Market Access (regulatory affair/pricing and reimbursement), Business Development, and Marketing. Survey results showed that the need of establishing the undergraduate program specializing in pharmaceutical industry is mixed, suggesting that although there is need for the educating personnel targeting pharmaceutical industry, the undergraduate program would not be an answer due to current PEET system. Our study concludes that in the example of pharmaceutical companies' recruitments shown in medical newspapers, pharmaceutical companies prefer pharmacy major in almost all fields of the pharmaceutical companies, yet the pharmaceutical companies still perceive the gap between current bachelor's degree holders(including pharmacy majors) and the ideal personnel required for advancing to the "top-class" pharmaceutical companies.

• 산업경영시스템학회지
• /
• 제44권3호
• /
• pp.192-206
• /
• 2021

The pharmaceutical industry is an industry that provides medicines related to the health and life of the people. The pharmaceutical industry is a traditional regulation industry with the characteristics of R&D(Research and Development), purchasing, manufacturing, distribution and consumption under strict government management. Until now, pharmaceutical companies have continued to make efforts to maintain competitiveness through patent management, new product development, and marketing. However, industries are rapidly changing, including rising costs for developing new products and expanding generic markets. As these changes and uncertainties in the management environment increase, efforts are required to improve the competitiveness of the pharmaceutical industry from a new perspective. In this study, we intend to examine the impact of SCM(Supply Chain Management) dynamic capability of pharmaceutical companies on corporate performance through partnerships to respond to market changes and uncertainties. It was determined that the agility, visibility and flexibility that constitutes the SCM dynamic capabilities would affect the performance of pharmaceutical companies. In this study, the importance of SCM dynamic capabilities and cooperative relationships was identified through surveys by SCM managers of pharmaceutical companies. Consequently, in the pharmaceutical industry, which is a regulatory industry, we have identified that SCM dynamic capabilities and cooperative relationships with partner companies have a significant impact on corporate performance.

• 한국임상약학회지
• /
• 제27권4호
• /
• pp.238-249
• /
• 2017

Background: Currently establishment of public pharmaceutical companies became an issue for securing stable supply of national essential drugs in order to respond appropriately to national public health crisis. Pharmacy students as future pharmacists need to be interested in drug related issues under the discussion in our society. This study aimed to investigate perceptions of pharmacy students on the national drug supply strategy through public pharmaceutical companies. Methods: A 20-items questionnaire designed for this study was used. Pharmacy students nationwide were enrolled in July 2017. They responded to questions through on-line survey program. Data were analyzed descriptively. Results: 160 students from 26 pharmacy schools participated. 5th and 6th grade students accounted for two-thirds, and one third aspired future jobs in pharmaceutical industry. Among responders, 71.3% was unaware of current national essential drugs, 52.5% did not know the Rare and Essential Drug Center, and 91.9% was unaware of the legislation on the supply and management of essential drugs. 82.5% favored the establishment of public pharmaceutical companies. 80.6% agreed that government should intervene in pharmaceutical market for ensuring drug accessibilities, 73.8% agreed that public pharmaceutical companies make possible to reach a goal of stable supply of pharmaceuticals, and 85.1% agreed that active compulsory license by public pharmaceutical companies is necessary. Conclusion: We found that pharmacy students recognized the need for governmental control to achieve social values of pharmaceuticals. More attention and participation of the pharmacy students as well as pharmacists in the process of national debate on public pharmaceutical companies are expected.

• 의료법학
• /
• 제12권2호
• /
• pp.65-117
• /
• 2011

This article analyzes the case (2008Da16776) which has the issue how patients have to prove causal relationship when patients claim against pharmaceutical companies alleging that patients were infected with virus due to contaminated blood products. The Supreme court held that: (1) if patients prove that they didn't have symptoms suggesting virus infection before administration of blood products, the virus infection had been confirmed after administration of blood products, and there were significant potential of contamination of the blood products with the virus, the defect in blood products or the negligence of pharmaceutical company in making blood products shall be presumed to cause the infection of the victim. (2) The pharmaceutical companies could reverse the presumption by proving the blood products were not contaminated, but the fact that the victims were treated with the blood products manufactured by other companies or had received blood transfusions is not enough to reverse the presumption. The case is the first decision whether the burden of proof about causal relationship could be reduced in pharmaceutical product liability lawsuit. Hereafter pharmaceutical product liability cases, it would be necessary to reduce the burden of proof about causal relationship in order to make substantive equality between patients and pharmaceutical companies.

• 융합경영연구
• /
• 제11권1호
• /
• pp.31-44
• /
• 2023

Purpose: This study aims to figure out the characteristics of corporate life cycle and resource input in terms of the sustainability diagnosis of pharmaceutical companies in Korea. Research design, data, and methodology: Using the Gompertz model under the assumption that companies have finite resources, this study tries quantitative interpretation of life cycle and resource input pattern for longevity companies with 25 years of experience among 158 pharmaceutical companies listed on Korean stock market based on maturity of revenue. Results: The study found revenue maturity through Gompertz model was statistically correlated with enterprise value. According to the life cycle analysis, more than 95% of 59 pharmaceutical companies were in the growth and maturity phase and have an average life cycle of 88 years and an average remaining life of 52 years. Regarding maturity profile of resource input, maturity of employees was generally high more than 60% and this meant there was jobless growth in Korean pharmaceutical industry. Conclusion: This study demonstrated there is a high statistical correlation between the maturity of a company's resource input and its revenue and enterprise value. It is believed that these results could be utilized as a basis for high fidelity function that predict revenue and enterprise value based on resource input information.

• 보건의료산업학회지
• /
• 제14권1호
• /
• pp.55-65
• /
• 2020

Objectives: To provide guidance for agency planning by identifying barriers faced by Korean pharmaceutical companies in global regulatory affairs. Methods: A questionnaire survey on global regulatory affairs was administered by email to personnel at Korean pharmaceutical companies. From a total of 60, 28 responses were collected. Respondents' companies were classified as small-sized or large-sized, based on whether their annual sales amounted to KRW 100 billion. Results: Small-sized companies were experiencing greater difficulties in receiving drug approvals from advanced countries, particularly during the Investigational New Drug (IND) and Good Manufacturing Practice (GMP) processes. Conclusions: Support measures to specifically help small-sized companies enter more advanced markets and further improved global regulatory guidelines that can meet large-sized companies' expectations are needed. Moreover, domestic and global regulatory standards should be harmonized to benefit both groups.

• 약학회지
• /
• 제56권2호
• /
• pp.116-125
• /
• 2012

Local pharmaceutical companies in Korea, which have grown focusing on domestic markets, have recently faced difficulties such as market saturation, price control policies and market-opening pressures by FTA. It seems to be an urgent issue for them to export pharmaceuticals to developed countries comprising the greater part of the global pharmaceutical market. Hence, this research was conducted to investigate and benchmark the strategies employed by India industry for the successful access to the global pharmaceutical markets. Drug policies as well as their influences on pharmaceutical market changes between India and Korea for the last 40 years have been searched and the differences have been comparatively analyzed. The pharmaceutical industry of India has the following strengths: low costs; experienced labor pool; excellent reverse-engineering skills; powerful IT; marketing capability; and established distribution network. After 2000, consolidations, M&A and alliances with domestic and multinational companies have been sharply increased in the industry of India. Indian companies unfolding both competition and cooperation with multinational corporations currently move up the value-added chain, and this enthusiastic strategy should be learned by local pharmaceutical companies.

• 보건의료산업학회지
• /
• 제7권1호
• /
• pp.69-82
• /
• 2013

The initial approach to this study is to focus on pharmaceutical companies' internal marketing activities for organizational diagnosis. By analysing the influence of internal marketing elements on the job satisfaction, organizational commitment, and turnover intention of pharmaceutical salespeople, this study aims at coming up with ways to strengthen the sales capacity and competitive edge of pharmaceutical companies through the salespeople's satisfaction. For 32 days between November 10th and December 12th of 2012, a total of 210 copies of questionnaires were given to the respondents and 203 of them except 7 with insufficient answers were used for the final analysis. The analysis result showed that internal communication, delegation of authority, and reward system among the elements of internal marketing activity had a positive influence on the workers' job satisfaction. The internal marketing activity elements did not influence the respondents' organizational commitment. Job satisfaction had a positive influence on their organizational commitment, while it had a negative influence of turnover intention. The conclusion section encapsulated the results of empirical analysis and proposed practical lessons regarding pharmaceutical companies' internal marketing.

• 유통과학연구
• /
• 제18권12호
• /
• pp.91-100
• /
• 2020

Purpose: The objective of this study is to deepen our understanding of the key factors that determine sustainability in terms of suppliers based on the transactions between suppliers (pharmaceutical companies) and buyers (medical institutions) in the pharmaceutical distribution industry. Research design, data and methodology: Transaction justice factors were derived from three main components: distributive, procedural and interpersonal, five hypotheses were set up. The respondents from the data collected through an online survey are sales staff of pharmaceutical companies. Total of 319 questionnaires are collected and used to verify the hypotheses through the SPSS 22.0 and AMOS 22.0 programs. Results: Justice of transactions perceived by the salesperson of pharmaceutical companies was found to have a significant effect on the relationship commitment. Among them, procedural justice was found to have greatest relative influences. In addition, relationship commitment was found to have a significant effect on sustainability performance. Thus, all hypotheses were adopted. Conclusions: The results of this study, can be used as basic data for the guidelines for fair trade between pharmaceutical companies and medical institutions. In addition, it is expected that the study will have significance in that it examined sustainability through transactions with buyers from the viewpoint of suppliers.

• 유통과학연구
• /
• 제12권5호
• /
• pp.33-40
• /
• 2014

Purpose - This paper aims to review cold chain management, especially in the pharmaceutical industry, to explore the cold chain process of delivering temperature-sensitive pharmaceutical products, and to identify areas for further development. Research design, data, and methodology - The paper, based on literature review and corporate analysis, reviews the development and status of the cold supply chain system, including its important role in the pharmaceutical industry. Results - Logistics in this field requires more stages than are typically needed. Due to the unique characteristics of the market, few companies can provide the services; currently, only few global companies with large networks and high technologies can afford to do so. Expanding pharmaceutical markets to meet global demand will require cold chain development, especially in "pharmerging" markets. Conclusions - Cold chain is a highly sensitive market in terms of products being carried within the chain that itself is a complex system. However, at the same time, it is a niche market with new opportunities. Hence, a sound cold chain infrastructure is needed to satisfy companies, governments, and customers for both commercial and public reasons.